| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
|
Medicine details |
|
| Medicine name | treosulfan (Trecondi®) |
| Formulation | 50 mg/ml powder for solution for injection/infusion |
| Reference number | 4034 |
| Indication | In combination with fludarabine prior to haematopoietic stem cell transplant as part of conditioning treatment prior to allogenic haematopoietic stem cell transplantation (alloHSCT) in paediatric patients older than one month and adult patients with malignant diseases |
| Company | medac GmbH |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/11/2019 |
| NICE guidance | TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Commercial arrangement | None |